Abstract:Abstract Background As the most common form of lymphoma, diffuse large B-cell lymphoma (DLBCL) is a clinical highly heterogeneous disease with variability in therapeutic outcomes and biological features. It is a challenge to identify of clinically meaningful tools for outcome prediction. In this study, we developed a prognosis model fused clinical characteristics with drug resistance pharmacogenomic signature to identify DLBCL prognostic subgroups for CHOP-based treatment. Methods The expression microarray data and clinical characteristics of 791 DLBCL patients from two Gene Expression Omnibus (GEO) databases were used to establish and validate this model. By using univariate Cox regression, eight clinical or genetic signatures were analyzed. The elastic net-regulated Cox regression analysis was used to select the best prognosis related factors into the predictive model. To estimate the prognostic capability of the model, Kaplan–Meier curve and the area under receiver operating characteristic (ROC) curve (AUC) were performed. Results A predictive model comprising 4 clinical factors and 2 pharmacogenomic gene signatures was established after 1000 times cross validation in the training dataset. The AUC of the comprehensive risk model was 0.78, whereas AUC value was lower for the clinical only model (0.68) or the gene only model (0.67). Compared with low-risk patients, the overall survival (OS) of DLBCL patients with high-risk scores was significantly decreased (HR = 4.55, 95% CI 3.14–6.59, log-rank p value = 1.06 × 10 −15 ). The signature also enables to predict prognosis within different molecular subtypes of DLBCL. The reliability of the integrated model was confirmed by independent validation dataset (HR = 3.47, 95% CI 2.42–4.97, log rank p value = 1.53 × 10 −11 ). Conclusions This integrated model has a better predictive capability to ascertain the prognosis of DLBCL patients prior to CHOP-like treatment, which may improve the clinical management of DLBCL patients and provide theoretical basis for individualized treatment.

Integrative Analysis of Prognosis Data on Multiple Cancer Subtypes using Penalization

Integrative analysis of multiple cancer prognosis studies with gene expression measurements.

Integrative Analysis Of High-Throughput Cancer Studies With Contrasted Penalization

Subtype Classification and Heterogeneous Prognosis Model Construction in Precision Medicine

Integrative Analysis of Cancer Omics Data for Prognosis Modeling

Identifying Gene-Environment Interactions for Prognosis Using a Robust Approach

Semiparametric Prognosis Models in Genomic Studies.

A Penalization Method for Estimating Heterogeneous Covariate Effects in Cancer Genomic Data.

Revealing genomic heterogeneity and commonality: A penalized integrative analysis approach accounting for the adjacency structure of measurements

A Robust Approach for Identifying Gene-Environment Interactions for Prognosis

Integrating Single-Cell and Bulk Expression Data to Identify and Analyze Cancer Prognosis-Related Genes

Improve the model of disease subtype heterogeneity by leveraging external summary data

Robust nonparametric integrative analysis to decipher heterogeneity and commonality across subgroups using sparse boosting

Gene-Based Association Analysis for Censored Traits Via Fixed Effect Functional Regressions

Identification of Predictive Pathways for Non-Hodgkin Lymphoma Prognosis.

A Generalized Integration Approach to Association Analysis with Multi-category Outcome: An Application to a Tumor Sequencing Study of Colorectal Cancer and Smoking

Identifying Oncogenes As Features for Clinical Cancer Prognosis by Bayesian Nonparametric Variable Selection Algorithm

Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer

Integrative analysis of pathological images and multi-dimensional genomic data for early-stage cancer prognosis.

Structural modeling using overlapped group penalties for discovering predictive biomarkers for subgroup analysis

An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy